港股异动|金斯瑞生物科技跌近6%预计中期利润盈转亏
格隆汇7月15日丨金斯瑞生物科技(01548.HK)盘初跌近6%,报17.88港元,成交680万港元,总市值332.5亿港元。金斯瑞生物科技上周五盘后公告,集团预期于截至2019年6月30日止6个月取得约2940万美元至4420万美元亏损,而2018年同期则取得盈利约1760万美元。董事会认为集团截至2019年6月30日止6个月的利润亏损主要由于以下因素:在传奇生物科技美国公司、传奇生物科技爱尔兰有限公司和Janssen Biotech, Inc.的合作专案上,为推进嵌合抗原受体T细胞(CAR-T)药物的开发、生产及商业化而在美国和中国开始的临床试验所产生的研发费用大幅提高;在开发新的细胞治疗管线(如针对血液瘤、实体肿瘤、感染性疾病及自身免疫病等疾病的治疗)及进一步加强自有的综合性细胞治疗平臺上的研发投入显著增加。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.